3627-62-1

Basic information

• Product Name: 1-methyl-4-phenylpiperidine-4-carbonitrile
• Synonyms: 1-methyl-4-phenylpiperidine-4-carbonitrile;4-CYANO-1-METHYL-4-PHENYLPIPERIDINE;3-Methyl-4-phenyl-4-piperidinenitrile;1-Methyl-4-phenyl-4-piperidinecarbonitrile
• CAS NO: 3627-62-1
• Molecular Formula: C₁₃H₁₆N₂
• Molecular Weight: 200.27954
• EINECS: 222-847-7
• Mol File: 3627-62-1.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 332.5 °C at 760 mmHg
• Flash Point: 141 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 0.000145mmHg at 25°C
• Refractive Index: 1.565
• CAS DataBase Reference: 1-methyl-4-phenylpiperidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-4-phenylpiperidine-4-carbonitrile(3627-62-1)
• EPA Substance Registry System: 1-methyl-4-phenylpiperidine-4-carbonitrile(3627-62-1)

Safety Data

• Hazardous Substances Data: 3627-62-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H16N2/c1-15-9-7-13(11-14,8-10-15)12-5-3-2-4-6-12/h2-6H,7-10H2,1H3

Upstream product

• 140-29-4 phenylacetonitrile 
• 51-75-2 nitrogen mustard 
• 100119-73-1 1,5-dichloro-3-cyano-3-phenylpentane 
• 74-89-5 methylamine 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 10469-27-9 α,α-bis(2-hydroxyethyl)phenylacetonitrile 
• 50599-78-5 4-dimethylamino-2-phenyl-butyronitrile 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 149-73-5 trimethyl orthoformate 
• 71258-18-9 1-benzyl-4-phenyl-piperidine-4-carbonitrile; hydrochloride 
• 854629-88-2 4-ethoxymethoxy-2-(2-ethoxymethoxy-ethyl)-2-phenyl-butyronitrile 
• 70179-05-4 2-phenyl-4-vinyloxy-2-(2-vinyloxy-ethyl)-butyronitrile 
• 55-86-7 mechlorethamine hydrochloride 

Downstream Products

• 7475-63-0 1-(1-methyl-4-phenylpiperidin-4-yl)propan-1-one 
• 774-52-7 1-methyl-4-phenylpiperidine 
• 1859-37-6 C-(1-methyl-4-phenyl-piperidin-4-yl)-methylamine 
• 96074-20-3 (1-methyl-4-phenyl-[4]piperidylmethyl)-(1-methyl-4-phenyl-[4]piperidylmethylen)-amine 
• 3627-48-3 pethidinic acid 
• 57-42-1 pethidine 
• 109161-93-5 1-methyl-4-phenyl-4-(1⁽²⁾H-tetrazol-5-yl)-piperidine 
• 96004-85-2 bis-(1-methyl-4-phenyl-[4]piperidylmethyl)-amine 
• 55623-58-0 (1-methyl-4-phenyl-piperidin-4-yl)-phenyl-methanone 
• 4220-10-4 (1-methyl-4-phenyl-piperidin-4-yl)-methanol 

Relevant articles and documents

Duraglutin artificial antigen and preparation method thereof

The invention provides a duramine artificial antigen and a preparation method thereof. The nitrile group of the 4-phenylpiperidine-4-carbonitrile is ingeniously reduced into the amino group; carboxylgroups capable of being used for crosslinking are introduced, so the characteristic original appearance of a duraglutin main ring is maintained; butanedioic anhydride is introduced, so acetyl functional groups on a duraglutin side chain is maintained on the said chain; the hapten synthesized by the process can maintain the characteristic group original appearance of duraglutin, and the synthesizedcorresponding artificial antigen has good specificity. The preparation process is simple, and the raw material source is not limited; the prepared artificial antigen can be used for animal immunization to obtain a corresponding duraglutin antibody, has strong antibody specificity, can be used in immunoassay, is suitable for research of various duraglutin immunoassay methods, and can be used as akey raw material for production of a duraglutin immunochromatographic kit.

HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease